Q32 Bio Announced That It Has Dosed The First Patients In Both The Part A Open-label Extension (OLE) And Part B Of The Signal-aa Phase 2A Clinical Trial Evaluating Bempikibart In Patients With Alopecia Areata (AA)
Author: Benzinga Newsdesk | April 16, 2025 07:00am